The invention belongs to an oral Chinese herbal preparation for treating post-traumatic brain syndrome, and the oral Chinese herbal preparation is a human medicinal product. The preparation is prepared from the following Chinese herbs in parts by weight: 10+ / -2 parts of Astragalus mongholicus, 10+ / -2 parts of American ginseng, 10+ / -2 parts of Angelica sinensis, 10+ / -2 parts of medlar, 10+ / -2 parts of the root of red-rooted salvia, 10+ / -2 parts of ligusticum wallichii, 10+ / -2 parts of root of common peony, 10+ / -2 parts of peach kernel, 10+ / -2 parts of Poria cocos, 10+ / -2 parts of pericarpium citri reticulatae, 10+ / -2 parts of plantain seed, 10+ / -2 parts of tabasheer, 10+ / -2 parts of rhizoma acori graminei, 10+ / -2 parts of gastrodia elata, 10+ / -2 parts of uncaria, 10+ / -2 parts of spina date seed, 10+ / -2 parts of amber powder and 6+ / -1.2 parts of honey-fried licorice root. Clinical effect observation proves that the total effective rate of the oral Chinese herbal preparation to the oral traditional Chinese medicine preparation is 94.07%, and has better treatment effect (P<0.01) compared with Western medicines such as Rotundine, piracetam, oryzanol and nimodipine for treating post-traumatic brain syndrome. Moreover, the Chinese herbal preparation has no obvious toxic or side effect, and can be taken for a long time. The dose of the preparation is small, and effective medicinal components are easy to release, can be absorbed quickly and can fully play the pharmaceutical effect. The preparation is convenient to carry, easy to take and beneficial to large-scale production.